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The human immunodeﬁciency virus type 1 (HIV-1) accessory
protein Vpu is an 81 amino acid oligomeric type 1 integral membrane
phosphoprotein (Cohen et al., 1988; Maldarelli et al., 1993; Strebel
et al., 1988), which is encoded exclusively in HIV-1 and related simian
immunodeﬁciency viruses (SIV), but not in HIV-2. Vpu has been
shown to induce degradation of the CD4 receptor by the ER-associated
protein degradation (ERAD) pathway (Schubert et al., 1992; Schubert
and Strebel, 1994; Willey et al., 1992a,b) and enhances virus particle
release from the plasma membrane (Gottlinger et al., 1993; Klimkait
et al., 1990). Both functions can be genetically dissected (Schubert and
Strebel, 1994). The cytoplasmic domain of Vpu contains a pair of
serine residues (at positions 52 and 56), which are constitutively
phosphorylated by the casein kinase 2 (CK-2) (Schubert et al., 1994).
The phosphorylation of these two serine residues in the cytoplasmic
domain is critical to induce CD4 degradation (Friborg et al., 1995;
Schubert et al., 1992, 1994; Schubert and Strebel, 1994). In contrast,
mutations within the transmembrane (TM) domain of Vpu retain the
ability to degrade CD4, but abrogate the ability to enhance virion
release (Schubert and Strebel, 1994). In addition, the TM domain of
Vpu was found to form a non-selective, voltage gated ion channel
(Ewart et al., 1996; Schubert et al., 1996b). Randomization of the TMdomain prevents Vpu's ion channel formation and impairs its ability
to regulate virus release (Schubert et al., 1996a). This suggested a
causal relation between the ion channel activity of Vpu and its
augmentation of virus release. However, the importance of Vpu's ion
channel activity for virus release has neither been experimentally
demonstrated nor mechanistically supported.
Recently, it was shown that Vpu enhances HIV-1 virion release by
counteracting a cellular restriction factor termed CD317 (also known
as tetherin, BST-2 or HM1.24) (Neil et al., 2008; Van Damme et al.,
2008). CD317 is an interferon-induced restriction factor, which
tethers virions to the cell surface, thereby impairing the release of
HIV-1, HIV-2, SIV and other enveloped viruses (Kaletsky et al., 2009;
Mansouri et al., 2009; Neil et al., 2007; Sakuma et al., 2009; Zhang et
al., 2009). CD317 is a type 2 TM protein and is targeted to cholesterol-
rich lipid rafts in the plasma membrane, the preferential site for HIV-
budding (Kupzig et al., 2003). CD317 also localizes in the endosomal
system, including the trans-Golgi network (Rollason et al., 2007).
CD317 has a unique topology, consisting of a 21 amino acid long
cytoplasmic tail, a TM domain with a membrane-spanning α-helix, a
110 amino acid ectodomain and a C-terminal glycosyl phosphatidy-
linositol (GPI) anchor. The latter mediates the localization into lipid
rafts (Hinz et al., 2010; Ishikawa et al., 1995; Perez-Caballero et al.,
2009). Recently, it was shown that the ectodomains of CD317 form
parallel dimers and that these homodimers tether virions to cellular
membranes (Yang et al., 2010). Furthermore, CD317 is constitutively
recycled through endosomal compartments (Varthakavi et al., 2006).
Vpu and CD317 interact via their TM domains and this interaction
is required for efﬁcient surface down-regulation of CD317 (Banning et
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Surface down-regulation and intracellular degradation of CD317
induced by Vpu occurs via lysosomes or proteasomes (Douglas
et al., 2009; Gofﬁnet et al., 2009; Iwabu et al., 2009; Mangeat et al.,
2009; Mitchell et al., 2009). Vpu recruits the ß-transducin repeat-
containing protein (ß-TrCP), a subunit of the Skp1-Cullin-F-box (SCF) E3
ubiquitin ligase complex,which binds to phosphorylated Ser-52 and Ser-
56 in the cytoplasmic domain of Vpu (Margottin et al., 1998; Mitchell
et al., 2009), and thereby the SCF E3 ubiquitin ligase complex induces
ubiquitination of CD317 on serine and threonine residues in the
cytoplasmic domain of CD317. This step is required for efﬁcient down-
regulation of CD317 from the cell surface (Tokarev et al., 2011).However,
Vpu does not increase the rate of internalization of CD317, suggesting
that Vpu acts at a post-endocytotic step to reduce cell surface levels of
CD317 (Douglas et al., 2009; Dube et al., 2010; Mitchell et al., 2009). It
has been shown that CK-2 inhibitors block the degradation of CD317 by
Vpu (Schindler et al., 2010), however, mutation of the ß-TrCP binding
motif only partially affects the virion release (Douglas et al., 2009;
Mitchell et al., 2009; Schubert et al., 1994, 1995) and does not induce a
speciﬁc re-localization of CD317 from the cell surface into a perinuclear
compartment (Dube et al., 2010). Recently, it was demonstrated that
mutation of several alanine residues, in particular the A14L-, A18H-, and
to a lesser extent also A18L-mutation impairs Vpu mediated counter-
action of CD317 (Skasko et al.; 2011; Vigan and Neil, 2010).
In order to unravel the importance of the ion channel activity for
the ability of Vpu to enhance virus release, we mutated the conserved
Ala-14 and Ala-18 in the TM domain of Vpu and analyzed the resulting
mutants for their ability to form ion channels and to counteract
CD317. Mutation of Ala-14 and Ala-18 to asparagine impairs the
efﬁciency of surface down-regulation of CD317. However, both
mutants still exhibit ion channel activity in 293T cells, indicating
that channel activity of Vpu is not sufﬁcient to support virus release.
Furthermore, to assess its relevance in CD317 counteraction, we
mutated Ser-23, which is essential for Vpu's ion channel activity, to
alanine (S23A) (Mehnert et al., 2008). Intriguingly, the S23A mutant
still efﬁciently interacted with CD317, and thus supported virus
release in the presence of CD317. Taken together, our data suggest
that the ion channel activity of Vpu is not critical for counteraction of
CD317.
Results and discussion
The VpuTM mutants A14N and A18N do not support virus release in the
presence of CD317.
Vpu has two main structural domains, the membrane-spanning
hydrophobic N-terminal TM domain and the C-terminal cytoplasmic
domain. While the TM domain is important for anchoring the protein
to the cellular membrane and to enhance virus release, the
cytoplasmic domain is crucial for the induction of CD4 degradation
(Bour et al., 1995; Schubert et al., 1994, 1995; Chen et al., 1993;
Friborg et al., 1995; Schubert and Strebel, 1994), and also to lesser
extent for degradation of CD317 (Douglas et al., 2009; Mitchell et al.,
2009; Schindler et al., 2010). Nevertheless, both functions can be
genetically separated (Schubert and Strebel, 1994). A Vpu mutant
containing a randomized TM sequence (RD) is incapable of supporting
virion release, as binding to CD317 is abrogated, but retained wt
activity for CD4 degradation (Banning et al., 2010; Schubert and
Strebel, 1994). The RD mutant contains a randomized TM sequence
with a conserved amino acid content and α-helical structure. The RD
mutant is integrated normally into membranes, it is able to form
homo-oligomers, it exhibits expression levels, protein stability and
sub-cellular localization similar to those of thewt Vpu (Schubert et al.,
1996a). However, it was shown that the RD mutant lost ion channel
activity and was unable to antagonize CD317 (Paul et al., 1998;
Schubert et al., 1996b; Tiganos et al., 1998). Hence, after scramblingthe amino acid sequence, a dissection of the two mechanisms, ion
channel formation and CD317 antagonism, is not possible.
Thus, in order to analyze whether ion channel activity of Vpu
correlates with viral particle release, several TM mutants were
generated. It was previously shown that Ser-23 of Vpu is essential
for ion channel activity (Mehnert et al., 2008). Therefore, we
generated a speciﬁc Vpu mutant, containing a point mutation in
which Ser-23 is replaced by alanine (Fig. 1A).
Recently, it has been demonstrated that several highly conserved
residues in the TM domain of Vpu, particularly Ala-18, Ala-14 and Trp-
22 are involved in counteraction of CD317 (Skasko et al., 2011; Vigan
and Neil, 2010). This stretch of conserved residues, which are located
on one face in the α-helix of the TM domain, regulates binding of Vpu
to CD317 and is highly conserved among Vpu proteins derived from
HIV-1 group M and N isolates (Skasko et al., 2011; Vigan and Neil,
2010). However, this particular TM motive is absent in Vpu proteins
derived from HIV-1 group O isolates, which are defective in CD317
antagonism, but retain the ability to down-regulate CD4 from the cell
surface (Sauter et al., 2009; Vigan and Neil, 2010). To analyze the
function of the TM domain of Vpu in CD317 down-regulation, we
mutated Ala-18 and Ala-14 to Asn in Vpu from the HIV-1 NL4-3
sequence (A18N; A14N). The A18N, A14N and S23A mutants were
introduced into the pΔR vector, an HIV-1NL4-3 based expression
construct that produces noninfectious virus like particles (VLPs), but
expresses authentic viral transcripts in the correct ratios (Gottwein
and Krausslich, 2005). HeLa cells, which constitutively express
endogenous CD317, were transfected with pΔR wt, ΔVpu, A18N,
A14N or S23A plasmids. 24 h post transfection VLPs were collected by
centrifugation and the amount of released virions was determined by
Western blot analysis (Fig. 1B). As expected, virus release was
severely reduced in the absence of Vpu (Fig. 1B lane 2). The A18N and
A14N mutations also substantially reduced the ability of Vpu to
support virus release (Fig. 1B, C), again conﬁrming that both alanine
residues are important for counteracting CD317 (Skasko et al., 2011;
Vigan and Neil, 2010). In contrast, mutation of Ser-23 has no effect on
viral particle release, indicating that the loss of channel activity does
not disturb CD317 counteraction (Skasko et al., 2011; Vigan and Neil,
2010). To conﬁrm these results, 293T cells were co-transfected with
pΔR or pΔRΔVpu and Vpu was complemented in transwith a plasmid
expressing either AU1-tagged Vpu wt or indicated mutants thereof,
together with Flag-tagged CD317. Overexpression of the A14N and
A18N mutants could not restore virus release, again conﬁrming that
Ala-14 and Ala-18 are required to antagonize CD317 (Fig. 1D, E).
Overexpression of the S23A mutant substantially enhances virus
release in presence of CD317, similar to wt Vpu (Fig. 1D, E).Vpu TM-mutants localize at the plasma membrane
Vpu was shown to localize in the ER, Golgi, endosomal structures
and at the plasma membrane (Klimkait et al., 1990; Pacyniak et al.,
2005; Varthakavi et al., 2006). In order to rule out the possibility that
mutations of Ala-18 and Ser-23 affect localization of Vpu at the plasma
membrane, cell surface biotinylation analysis was performed. This is
particularly important, as it was shown previously that mutation of
Ala-18 to His (A18H) resulted in abnormal retention of Vpu in the ER
(Hout et al., 2006; Skasko et al., 2011). 293T cells were transfected
with either AU1-tagged Vpu, A18N or S23A and Flag-tagged CD317, as
a control. 24 h post transfection cell surface proteins were biotiny-
lated with Sulfo-NHS-LC-biotin for 15 min at 4 °C. Cells were
subsequently lyzed and biotinylated proteins were immunoprecipi-
tated with immobilized Streptavidin, separated by SDS-PAGE and
analyzed byWestern blot. As shown in Fig. 2, CD317, Vpu and both TM
mutants were efﬁciently immunoprecipitated with Streptavidin. The
ribosomal P0 antigen, which localizes in the cytoplasm, is not
detectable after immunoprecipitation. Hence, in contrast to the
Fig. 1. The ability of Vpu TMmutants to antagonize CD317. (A) Schematic representation of the amino acid sequence of the transmembrane domain of Vpuwt, A18N, A14N, S23A and
RD. (B) A18N and A14N mutations abrogate augmentation of virus release. HeLa cells were transfected with either pΔR wt, ΔVpu, A18N, A14N and S23A plasmids. 24 h post
transfection VLPs were pelleted and the amount of released virions was determined byWestern blot. In addition, cells were lyzed and analyzed byWestern blot, using anti-Vpu and
anti-CA antibodies. (C) Quantiﬁcation of Gag release of 3 independent experiments. (D) Overexpression of the A18N and A14N mutants together with CD317 substantially reduced
virion release. 293T cells were co-transfected with either pΔR, pΔRΔVpu or pΔRΔVpu complemented in trans with a plasmid expressing either Vpu, A18N, A14N and S23A and
Flag-tagged CD317. 24 h post transfection VLPs were pelleted and the amount of released virions was determined by Western blot. In addition, cells were lyzed and analyzed by
Western blot, using anti-Vpu, anti-CA- and anti-Flag antibodies. (E) Quantiﬁcation of Gag release of 3 independent experiments.
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affect trafﬁcking of Vpu to the plasma membrane.
The A18N mutant exhibits a normal sub-cellular distribution as wt Vpu
To investigate whether the A18N mutant exhibits a normal sub-
cellular distribution as wt Vpu, we analyzed the sub-cellularlocalization of wt Vpu, the RD, the A18H and the A18N mutants by
confocal microscopy. HeLa cells were transfected with Vpu-YFP fusion
proteins (Banning et al., 2010), containing the mutations A18H, A18N
or RD. 24 h post transfection the cells were ﬁxed, permeabilized and
stained for Calnexin, a Ca2+-binding protein that is primarily located
in the ER. Conﬁrming recent results (Skasko et al., 2011), the A18H
mutant is retained in the ER, leading to efﬁcient co-localization with
Fig. 2. Surface biotinylation of Vpu and TM mutants. 293T cells were transfected with either Flag-tagged CD317 or AU1-tagged Vpu wt, A18N or S23A. 24 h post transfection, cell
surface-expressed proteins were biotinylated. Upon cell lysis, biotinylated proteins were captured with immobilized streptavidin, separated by SDS-PAGE and analyzed byWestern
blot. Vpu and CD317 were detected, using polyclonal anti-Vpu and anti-Flag antibodies.
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analysis, which revealed substantially reduced levels of the A18H
mutant at the plasma membrane compared to wt Vpu (data not
shown). In contrast, the A18N and RD mutants co-localized less
extensively with Calnexin, showing similar to Vpu wt a more
endosomal sub-cellular distribution. To conﬁrm an ER retention of
the A18H mutant, cells were treated with the ER transport inhibitor
Brefeldin A (BFA). BFA is a fungal metabolite that blocks protein trafﬁc
from the ER to the Golgi system and blocks the Vpu-dependent
enhancement of virion release, but not the Vpu-induced decay of CD4
(Schubert and Strebel, 1994). In the presence of BFA, the A18N,
A18H and RD mutants as well as Vpu wt are retained in the ER and
co-localized efﬁciently with Calnexin (Fig. 3B). Overall, these data
show that in contrast to the A18H mutant, the A18N mutation does
not affect sub-cellular distribution of Vpu.
Monitoring ion channel activity of Vpu and Vpu TMmutants analyzed by
patch-clamp measurements
In silico studies of Vpu indicate that the TM domain of Vpu forms
pentameric structures (Lopez et al., 2002; Moore et al., 1998), and
oligomerization of the TM domain of Vpu has been shown to result in
the formation of ion channels (Ewart et al., 1996; Schubert et al.,
1996a). To test the A18N mutant of Vpu for its ability to form ion
channels, the protein was expressed in 293T cells and the membrane
currents of transfected cells were then recorded with the patch-clamp
technique in the whole cell conﬁguration. The Vpu wt protein, which
was extensively studied in several systems, served as a positive
control (Ewart et al., 1996; Schubert et al., 1996b). The following three
negative controls were employed: ﬁrst, untransfected 293T cells;
second, the RD mutant, which lacked channel activity in Xenopus
laevis oocytes and planar lipid bilayers (Schubert et al., 1996b); and
third, the S23A mutant, which did not show channel activity after
reconstitution in lipid bilayers (Mehnert et al., 2008). The data shown
in Fig. 4B demonstrate that the level of all Vpu constructs in the
plasma membrane of the cells was indeed comparable.
Untransfected 293T cells exhibited the typical electrical charac-
teristics of these cells with a small outward rectiﬁer and a very smallinward current. A typical measurement of an untransfected cell with
the corresponding current/voltage (IV) relation is shown in Fig. 4A.
Characteristic for all untransfected cells was a high ratio of steady
current at +80 mV and the current at −140 mV. The mean ratio
I+80mV/I−140mV obtained from 5 untransfected cells is summarized in
Fig. 4C. The same high ratio I+80mV/I−140mV reﬂecting a minute
inward current and some outward rectiﬁer was observed in cells
expressing both, the S23A mutant or the RD mutant (Fig. 4A, C). This
implies that these proteins did, as expected, not generate any
conductance in 293T cells. Cells expressing Vpu wt exhibit an overall
larger conductance. In particular the inward conductance in these
cells was much larger than in the negative controls (Fig. 4A). As a
result of a Vpu generated conductance, the I/V relation of these cells
became quasi linear. This is reﬂected in a robust low I+80mV/I−140mV
ratio (Fig. 4C). Cells expressing the A18N or A14Nmutants exhibit the
same electrical features as those expressing Vpu wt, i.e., they have a
higher inward current and a small I+80mV/I−140mV ratio (Fig. 4C). The
exemplary current responses with the corresponding current/voltage
curves of 293T cells expressing Vpu wt or the A18N or A14N mutants
are shown in Fig. 4A. The results of these experiments show that the
A18N and A14N mutants are functional channels and generate
membrane conductance in the same way as the wt protein. Therefore,
we conclude that ion channel activity of Vpu is dispensable for
counteraction of CD317, as the A18N mutant does not support virus
release in presence of CD317 (Fig. 1), however, it still generates ion
channel activity.
Binding of Vpu TM mutants to CD317
It was demonstrated that Vpu binds to CD317 via its TM domain,
and that this binding is essential to antagonize CD317 (Banning et al.,
2010; Rong et al., 2009). Furthermore, it was previously shown that
mutation of Ala-14 to leucine abrogates the ability of Vpu to interact
with CD317 (Vigan and Neil, 2010). To investigate whether the A14N,
A18N or the S23A mutations inﬂuence the interaction of Vpu and
CD317, co-immunoprecipitation experiments were performed. 293T
cells were co-transfected with plasmids expressing AU1-tagged Vpu
and mutants thereof, together with Flag-tagged CD317. 24 h post
Fig. 3. Sub-cellular distribution of Vpu TM mutants in presence or absence of Brefeldin A. HeLa cells were transfected with either Vpu wt, A18H-, A18N- or RD-YFP fusion proteins
(green) either in absence (A) or presence (B) of BFA. 5 h after transfection, BFA (10 μg/ml) was added to the cells and 24 h post transfection the cells were ﬁxed, permeabilized and
stained for Calnexin (red).
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Fig. 4. The ability of Vpu and TM mutants to form ion channels. (A) Exemplary current responses of 293T cells transfected with either AU1-tagged Vpu- wt, RD-, S23A-, A18N or
A14N-IRES-GFP, respectively (left side) and corresponding steady-state I/V relationships (right side). Currents were measured in whole cell conﬁguration in a 50 mMKCl containing
bath solution and elicited by standard voltage protocol from holding voltage (0 mV) to test voltages between +80 and−160 mV. (B) Cells were lyzed and protein expression was
analyzed byWestern blot, using anti-Vpu and anti-GFP antibodies. (C) Ratio of steady state currents at +80 mV and−140 mV (I+80mV/I−140mV) of 293T cells transfected with either
Vpu wt, RD, S23A, A18N or A14N, respectively. Values are the means of n=5 cells±SEM.
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a monoclonal anti-AU1 afﬁnity matrix. Immunoprecipitated material
was analyzed for the presence of CD317 by Western blot, using Flag-
speciﬁc antibody. CD317- and Vpu expressionwas detected with anti-
Flag and anti-Vpu-serum, respectively. As shown in Fig. 5A and in
agreement with previous data (Banning et al., 2010, Rong et al., 2009),
CD317 was efﬁciently co-immunoprecipitated with wt Vpu, but not
with the RD mutant (Fig. 5A, lanes 4, 7). As expected, the S23A
mutant, which is able to antagonize CD317 (Fig. 1), efﬁciently binds
CD317 (Fig. 5A, lane 6). In agreement with recent data (Vigan and
Neil, 2010), the A14N mutation abrogates the interaction to CD317
(Fig. 5A, lane 12). Notably, the A18N mutant still binds to CD317,
however, it appears to be attenuated when compared to Vpu wt.
To conﬁrm whether mutations of Ala-18 affect the interaction
between Vpu and CD317, we employed a recently developed FACS-
based Försters resonance energy transfer (FRET) assay (Banning et al.,
2010) to determine the binding of Vpu and CD317 in living cells
(Fig. 5B). To this end, a CFP-CD317 plasmid was co-transfected with a
Vpu-YFP plasmid or TMmutants in 293T cells. In control experiments,
the S52A phosphorylation mutant, containing a functional TM
domain, did not reduce the frequency of FRET positive cells (Banning
et al., 2010). In contrast, the RD mutant expressed-together with
CD317- showed a strongly diminished FRET signal, and mutation of
Ala-18 to His in Vpu impaired binding of Vpu to CD317. This is
consistent with recent results, which demonstrated a reduced
interaction between Vpu A18H and CD317 (Skasko et al., 2011).
Interestingly, the A18N mutant showed also a strongly reduced FRET
signal similar to the RD mutant, indicating that binding to CD317 is
attenuated (Fig. 5B). To conﬁrm these results, Vpu-YFP fusion proteins
and Flag-tagged CD317 were co-immunoprecipitated with anti-Vpuserum, separated by SDS-PAGE and analyzed by Western blot, using
anti-Flag and anti-GFP antibodies (Fig. 5C). Vpu and the A18Hmutant
were efﬁciently immunoprecipitated with CD317, but not the RD
mutant (Fig. 5C, lanes 5, 7, 8). Compared to the A18Hmutant, binding
of the A18N mutant to CD317 is even more attenuated. Although still
detectable in the IP (Fig. 5C, lane 6), the interaction is apparently too
weak to be detected by FRET (Fig. 5B). Taken together, these data
indicate that Ala-18 in Vpu somehow participates in the binding to
CD317. However, while mutations of Ala-14 and Trp-22 almost
completely eliminate binding of Vpu to CD317 (Vigan and Neil, 2010,
and data not shown), mutation of Ala-18 merely attenuates binding.
Yet, it is still not clear whether this defect in binding alone is the
underlying reason for the inefﬁcient counteraction of CD317 by the
A18N mutant.
Vpu A18N induces degradation of CD4, but is impaired in down-
regulation of CD317 from the cell surface
Although the precise mechanism by which Vpu counteracts CD317
is still unclear, it was shown that augmentation of virus release by Vpu
correlates with its ability to down-regulate CD317 from the cell
surface (Mitchell et al., 2009; Rong et al., 2009; Skasko et al., 2011;
Tokarev et al., 2011). In order to investigate whether the TM
mutations affect the ability of Vpu to down-regulate cell surface
levels of CD317, HeLa cells were transfected with plasmids expressing
Vpu wt or TM mutants along with GFP translated via an internal
ribosomal entry site (Vpu-IRES-GFP) to monitor transfected cells. 24 h
post transfection cells were harvested, stained for cell surface CD317,
using a CD317-speciﬁc monoclonal antibody and analyzed by ﬂow
cytometry. Expression of Vpu proteins was controlled byWestern blot
Fig. 5. Interaction of Vpu and TM mutants with CD317. (A) 293T cells were co-transfected with AU1-tagged Vpu- wt, A18N-, RD-, S23A- or A14N-IRES-GFP and Flag-tagged CD317.
24 h post transfection cells were lyzed and Vpu immune complexes were isolated from cell detergent extracts by immunoprecipitation with monoclonal AU1 afﬁnity matrix and
analyzed for the presence of CD317 by Western blot with anti-Flag antibody. CD317- and Vpu expression were detected with either anti-Flag or anti-Vpu antibody. (B) FACS-based
FRET analysis of 293T cells transfected with YFP-Vpu- and CFP-CD317 expression plasmids. Mean and SD are derived of two independent experiments with duplicate transfections.
(C) 293T cells were transfected with the indicated Vpu-YFP fusions and a FLAG-tagged CD317. Vpu immune complexes were isolated from cell detergent extracts by
immunoprecipitation, using anti-Vpu rabbit serum and analyzed for the presence of CD317 by Western blot with anti-FLAG. YFP-fusion proteins were detected with anti-GFP
antibody.
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was calculated as mean ﬂuorescence intensity (MFI) of CD317
expression in GFP positive cells relative to GFP negative cells. Fig. 6A
shows that Vpu, as well as the S23Amutant, efﬁciently down-regulate
the cell surface expression of CD317 approximately by 4-fold
(Fig. 6A). As expected, the RD mutant completely failed to induce
down-regulation of CD317 from the cell surface. In contrast, the A18N
mutant and the A14N mutant (data not shown) were substantially
attenuated in down-regulation of CD317 (Fig. 6A). GFP positive cells
expressing the A18N mutant displayed similar amounts of CD317 at
the cell surface when compared to GFP negative cells. Nonetheless,
some down-regulation was detected at high GFP expression levels,indicating that the mutant retains some activity at high expression
levels (Fig. 6A).
Vpu induces CD4 degradation by the ERAD pathway via recruiting
ß-TrCP, a subunit of the SCF E3 ubiquitin ligase complex (Schubert et
al., 1992, 1994; Willey et al., 1992a,b). In order to conﬁrm that the
introduced TM mutations in Vpu selectively interfere with CD317
down-regulation and do not render the protein completely inactive,
we examined the ability of the A18N and S23A mutants to induce
down-regulation of CD4. CD4 positive HeLa cells were transfected
with Vpu-IRES-GFP plasmids encoding for Vpu wt or VpuTMmutants.
24 h post transfection the cells were harvested and stained for surface
CD4, using a monoclonal CD4-speciﬁc antibody and analyzed by ﬂow
Fig. 6. The A18 mutant is speciﬁcally defective in CD317 antagonism. (A) HeLa cells were transfected with either Vpu-IRES-GFP or TM mutants. 24 h post transfection cells were
harvested and stained for surface CD317, using a monoclonal CD317-speciﬁc antibody and analyzed by ﬂow cytometry. In addition, cells were lyzed and analyzed by Western blot,
using anti-GFP and anti-Vpu antibodies. Summary of relative CD317 surface expression from 3 independent experiments is given below. (B) CD4 positive HeLa cells were transfected
with either GFP, AU1-tagged Vpu-IRES-GFP or VpuTM mutants. 24 h post transfection cells were harvested and stained for surface CD4, using a monoclonal CD4-speciﬁc antibody
and analyzed by ﬂow cytometry. In addition, cells were lyzed and analyzed byWestern blot, using anti-GFP or anti-Vpu antibodies. Summary of relative CD4 surface expression from
3 independent experiments is given below.
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conﬁrmed byWestern blot analysis (Fig. 6B). The data conﬁrm that all
TM mutants efﬁciently induced surface down-regulation of CD4,
indicating that the cytoplasmic domains of themutants are functional.
Taken together, our results show that the ion channel activity of
Vpu is dispensable for counteraction of CD317. The ability of Vpu to
enhance virus release directly correlates with its ability to down-
regulate cell surface CD317, but not with its ion channel function.
Until now, no biological role for the ability of Vpu to form ion
channels has been established so far. Nevertheless, the ion channel
might still be important for other functions of Vpu. Very recently, Vpu
was shown to downmodulate NTB-A (SLAMF6) on infected T cells,
thereby protecting the infected cells from lysis by natural killer (NK)
cells (Shah et al., 2010). Yet, the precise mechanism how Vpu down-
regulates NTB-A has not been unraveled so far. Furthermore, it wasshown that Vpu inhibits cell surface expression of CD1d in dendritic
cells (DCs), thereby retaining the protein in early endosomal
compartments (Moll et al., 2010). In both novel functions of Vpu,
the role of the ion channel activity of Vpu has not been investigated so
far. Thus, although well established, the ion channel activity of Vpu
might be important for some still unknown functions of Vpu.
Materials and methods
Site-directed mutagenesis and plasmid constructions
All plasmids containing HIV-1 sequences are derivatives of the
infectious molecular clone pNL4-3 (Adachi et al., 1986). The pΔR
plasmid contains a primer binding site deletion and a reverse
transcriptase (RT) active-site mutation and produces noninfectious
83S. Bolduan et al. / Virology 416 (2011) 75–85VLPs (Gottwein and Krausslich, 2005). Mutations were introduced by
site-directed mutagenesis (Quick change Kit, Stratagene), using
oligonucleotides, containing indicated changes. For cloning of
pΔRΔVpu a 205-bp EcoRI–NheI fragment from the pNL4-3vpuDEL-1
carrying a 41-bp out-of-frame deletion in vpu (Klimkait et al., 1990),
was introduced into the pΔR expression vector. Mutations were also
introduced into the previously described pCG-IRES-GFP vector,
expressing AU1-tagged Vpu together with GFP from a bicistronic
mRNA (Sauter et al., 2009; Schindler et al., 2003) and the pEYFP-Vpu
plasmid, encoding a Vpu-YFP fusion protein (Banning et al., 2010).
The pCMV-Flag-CD317 expression vector was described elsewhere
(Banning et al., 2010).
Cells culture and transfection
HeLa cells and HEK293T were cultivated in Dulbecco's modiﬁed
Eagle's medium (DMEM) supplemented with 10% heat inactivated
fetal calf serum (FCS), 100 U/ml penicillin and 100 mg/ml
streptomycin.
For transfection, 9×105 cells/well were seeded in 6-well plates
1 day prior to transfection. The next day transfection was performed
using Lipofectamine 2000TM (Invitrogen), according to the manufac-
turer's protocol.
Virus release assay
HeLa cells were transiently transfected with either pΔR or
pΔRΔVpu complemented in trans with a plasmid expressing either
Vpu, A18N, A14N or S23A, using Lipofectamine 2000TM. Cells and
virions were harvested 24 h post transfection. Cells were lyzed in
RIPA-buffer (1% NP-40, 0.5% Na-DOC, 0.1% SDS, 0.15 M NaCl; 50 mM
Tris–HCl pH 7.4; 5 mM EDTA) and analyzed byWestern blot. Cells and
cell debris from virus containing supernatant were removed by
centrifugation at 1000×g for 5 min and 8000×g for 10 min. Virions
were puriﬁed by centrifugation through 20% sucrose at 20,000×g for
90 min, re-suspended in 1 ml of PBS, pelleted again for 20,000×g for
90 min to remove serum albumins and ﬁnally analyzed by Western
blotting.
Co-immunoprecipitation assay
For co-immunoprecipitation, 9×105 293T cells were transfected
with either 150 ng pCMV-FLAG-CD317 or 1 μg AU1-tagged Vpu and
TM mutants or Vpu-YFP fusions proteins and TM mutants expression
plasmids, as indicated. Cells were lyzed in digitonin lysis buffer
(140 mM NaCl, 10 mM Tris–HCl, pH 7.4, 1 mM EDTA, protease
inhibitor mixture (Roche), 1% (w/v) digitonin (Calbiochem)), in
order to solubilize transmembrane proteins. Cleared lysates were
incubated with monoclonal AU1 afﬁnity matrix (Covance) or anti-
Vpu-serum for 90 min on ice. Immune complexes were washed four
times in wash buffer (lysis buffer with 0.1% digitonin), separated in
12% SDS-PAA gel and analyzed by Western blot with M2-anti-FLAG-
HRP antibody (Sigma). Vpu expression was detected, using a
polyclonal anti-Vpu antiserum (rabbit), directed against the hydro-
philic C-terminal domain of Vpu.
FACS-based FRET-assay
Flow cyometric measurement of FRET and the according gating
strategy were performed as already described (Banning et al., 2010).
Brieﬂy, 9×105 293T-cells were seeded in a 6-well plate and
transfected, using the calcium phosphate method. Cells were
harvested and assayed 1 day post transfection for FACS-FRET analysis
in a FACSAria (BD Bioscience). ECFP and FRET were measured by
exciting cells with the 405 nm laser and ECFP-emission was collected
with a standard 450/40 ﬁlter, while FRETwasmeasuredwith a 529/24ﬁlter. EYFP was excited with the 488 nm laser and emission was
collected with a 529/24 ﬁlter. At least two thousand CFP/YFP positive
cells were analyzed for FRET.
Flow cytometric analysis of Vpu mediated CD317 and CD4 down-
regulation
HeLa cells were transfected with pCG-Vpu-AU1-IRES-GFP or TM
mutants. 24 h post transfection the cells were harvested and stained
for surface CD317, using an anti-CD317 monoclonal antibody
(Abnova) and chicken anti-mouse Alexa647 conjugated secondary
antibody (Molecular Probes, Invitrogen). CD317 surface expression on
GFP positive cells was then analyzed in a FACS LSRII, using FACSDiva
software (BD Biosciences). Data analysis was performed, using FCS
Express V3 software (De Novo).
CD4 positive HeLa cells were transfected with either pCG-Vpu-
AU1-IRES-GFP or Vpu TM mutants. 24 h post transfection the cells
were harvested and stained for surface CD4, using an anti-human CD4
APC conjugated antibody (Invitrogen). CD4 surface expression on GFP
positive cells was then analyzed in a FACS LSRII, using FACSDiva
software (BD Biosciences). Data analysis was performed, using FCS
Express V3 software (De Novo).
Cell surface protein biotinylation
Cell surface proteins were biotinylated with EZ-Link Sulfo-NHS-
LC-Biotin according to the manufacturer's protocol (Thermo scientif-
ic). Brieﬂy, cells were washed three times with ice-cold phosphate-
buffered saline (PBS), and primary amines of the membrane proteins
exposed to the exterior of the cells were biotinylated with Sulfo-NHS-
LC-biotin for 15 min at 4 °C. The cells were washed and lyzed with
RIPA buffer. Biotinylated proteins were precipitated at 4 °C with
immobilized Streptavidin (Thermo Scientiﬁc Pierce). Precipitated
material was washed four times in RIPA buffer, separated in 12% SDS-
PAA gel and analyzed by Western blot, using polyclonal anti-Vpu
antiserum (rabbit), M2-anti-FLAG-HRP antibody (Sigma) for detec-
tion of CD317 and human anti-Ribosomal P antibody (Immunosion,
INC) to detect ribosomal P antigen.
Immunoﬂourescence microscopy
HeLa cells were transfected with either Vpu wt, A18H-, A18N- or
RD-YFP fusion proteins. 5 h after transfection BFA (10 μg/ml) was
added and 24 h post transfection the cells were ﬁxed in 3%
formaldehyde, permeabilized, using 0.1% Triton X-100 in PBS and
stained for Calnexin, using anti-Calnexin antibody (Acris). Images
were obtained using a Leica TCS SP5 confocal microscope with the
63× objective and analyzed by Adobe Photoshop software.
Electrophysiological measurements
293T cells were transiently transfected with AU1-tagged Vpu or
TM mutants, using liposomal transfection reagent TurboFect™
(Fermentas). 24 h post transfection cells were washed with PBS,
dispersed with Accutase® (SIGMA-Aldrich) and seeded into new
culture dishes with lower density. For the electrophysiological
measurements, the culture medium was removed and replaced by
bath solution. The bath solution contained 1.8 mMCaCl2, 1 mMMgCl2,
5 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
and 50 mM KCl. The pH was adjusted to 7.4 with KOH. The osmolarity
was adjusted to 330 mOsmol with mannitol. The pipette solution
contained 130 mM D-potassium-gluconic acid, 10 mM NaCl, 5 mM
HEPES, 0.1 mM guanosine triphosphate (Na salt), 0.1 μM CaCl2, 2 mM,
MgCl2, 5 mM phosphocreatine and 2 mM adenosine triphosphate
(ATP, Na salt); the pH was adjusted to 7.4 with KOH, the osmolarity
was adjusted to 330 mOsmol with mannitol.
84 S. Bolduan et al. / Virology 416 (2011) 75–85Single cell patch-clamp measurements were performed at room
temperature in whole-cell conﬁguration, using standard methods
(Hamill and Marty, 1981) with an EPC-9 patch-clamp ampliﬁer
(HEKA, Lamprecht, Germany. Cells were clamped from a holding
voltage (0 mV) to test voltages between+80 and−160 mV and back
to post potential (−80 mV). The data were acquired and analyzed
with the Pulse software (HEKA, Lamprecht, Germany).
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